Liposomal Bupivacaine in Vaginal Hysterectomy

PHASE4TerminatedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

September 3, 2019

Primary Completion Date

July 23, 2021

Study Completion Date

July 23, 2021

Conditions
Vaginal Hysterectomy
Interventions
DRUG

Liposomal bupivacaine

Liposomal bupivacaine is a novel formulation of local bupivacaine and allows prolonged release of the medication, thereby providing longer lasting effects. It is approved by the FDA and has been shown to provide excellent pain control after surgery.

DRUG

Bupivacaine Hydrochloride

We currently administer local plain bupivacaine during vaginal hysterectomy to decrease pain in the postoperative period. Bupivacaine is an anesthetic that works by blocking nerve conduction and producing a numbing effect.

Trial Locations (1)

85054

Mayo Clinic in Arizona, Phoenix

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Pacira Pharmaceuticals, Inc

INDUSTRY

lead

Mayo Clinic

OTHER

NCT03907033 - Liposomal Bupivacaine in Vaginal Hysterectomy | Biotech Hunter | Biotech Hunter